The Federal Reserve raised its economic growth forecast for 2026, and Wall Street expects another strong year for the U.S.

On April 2, the president unveiled his touted tariff and trade policy. It featured a sweeping 10% global tariff, along with ...

In the third quarter, Netflix generated revenue that climbed 17% year over year to $11.5 billion, driving its adjusted ...

If you're hoping for much higher returns in the new year, you could be in luck. Here are three S&P 500 stocks that could soar ...

Shares of Axon have plummeted more than 30% since their highs in August. The stock sank in 26% in November alone after Axon's ...

Strategists are divided on valuations — specifically, on the direction of the forward price-earnings (P/E) ratio as it hovers ...

The queasiness about the AI trade involves its uses, the enormous cost of developing it, and whether consumers ultimately ...

The Chemours Company (NYSE:CC) is one of the Best Small Cap Value Stocks to Buy. The Chemours Company (NYSE:CC) is up more ...

All told, the S&P 500 fell 73.59 points to 6,827.41. The Dow Jones Industrial Average dropped 245.96 to 48,458.05, and the ...

Demand for Big Data services is increasing. Palantir, a leader in the field, should benefit. Here are the forecasts and price ...

These five ultra-high-yield passive income stocks trade for less than $10 a share and have Buy ratings from top Wall Street firms.

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.